We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

22 hedge funds and large institutions have $4.33M invested in CASI Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

63% more capital invested

Capital invested by funds: $2.65M → $4.33M (+$1.68M)

2.94% more ownership

Funds ownership: 18.26% → 21.2% (+2.9%)

8% less funds holding

Funds holding: 24 → 22 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
5
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$433K
2
FCMV
Foresite Capital Management VI
California
+$344K
3
Two Sigma Investments
Two Sigma Investments
New York
+$59.4K
4
GSC
Ground Swell Capital
South Carolina
+$18.1K
5
Renaissance Technologies
Renaissance Technologies
New York
+$8.38K

Top Sellers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
-$52.1K
2
Citadel Advisors
Citadel Advisors
Florida
-$42.8K
3
WSCM
Wellington Shields Capital Management
New York
-$38K
4
TSS
Two Sigma Securities
New York
-$13.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$12K

CASI Hedge Fund Activity: Q3 2025 in Review

22 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2025, worth a combined $4.33M — up 63% from $2.65M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CASI and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Bank of America, adding an estimated $433K. The largest seller was ADAR1 Capital Management, exiting entirely with an estimated $52.1K sold.

  • 22 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2025, down from 24 in Q2 2025.
  • Funds reported $4.33M of CASI Pharmaceuticals stock for Q3 2025, up 63% quarter-over-quarter.
  • 3 funds opened new CASI Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of -2 holders.
  • The largest CASI Pharmaceuticals buyer in Q3 2025 was Bank of America, an estimated $433K added.
  • The largest CASI Pharmaceuticals seller in Q3 2025 was ADAR1 Capital Management, an estimated $52.1K sold.

Based on aggregated 13F filings for Q3 2025.